» Articles » PMID: 21792861

Reported Referral for Genetic Counseling or BRCA 1/2 Testing Among United States Physicians: a Vignette-based Study

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2011 Jul 28
PMID 21792861
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Genetic counseling and testing is recommended for women at high but not average risk of ovarian cancer. National estimates of physician adherence to genetic counseling and testing recommendations are lacking.

Methods: Using a vignette-based study, we surveyed 3200 United States family physicians, general internists, and obstetrician/gynecologists and received 1878 (62%) responses. The questionnaire included an annual examination vignette asking about genetic counseling and testing. The vignette varied patient age, race, insurance status, and ovarian cancer risk. Estimates of physician adherence to genetic counseling and testing recommendations were weighted to the United States primary care physician population. Multivariable logistic regression identified independent patient and physician predictors of adherence.

Results: For average-risk women, 71% of physicians self-reported adhering to recommendations against genetic counseling or testing. In multivariable modeling, predictors of adherence against referral/testing included black versus white race (relative risk [RR], 1.16; 95% confidence interval [CI], 1.03-1.31), Medicaid versus private insurance (RR, 1.15; 95% CI, 1.02-1.29), and rural versus urban location. Among high-risk women, 41% of physicians self-reported adhering to recommendations to refer for genetic counseling or testing. Predictors of adherence for referral/testing were younger patient age [35 vs 51 years [RR, 1.78; 95% CI, 1.41-2.24]), physician sex (female vs male [RR, 1.30; 95% CI, 1.07-1.64]), and obstetrician/gynecologist versus family medicine specialty (RR, 1.64; 95% CI, 1.31-2.05). For both average-risk and high-risk women, physician-estimated ovarian cancer risk was the most powerful predictor of recommendation adherence.

Conclusion: Physicians reported that they would refer many average-risk women and would not refer many high-risk women for genetic counseling/testing. Intervention efforts, including promotion of accurate risk assessment, are needed.

Citing Articles

Challenges for clinical application of "TRACEBACK" study: testing of historical Tubo-Ovarian cancer patients for hereditary risk genes.

Sekine M, Isobe M, Nishino K, Adachi S, Suda K, Yoshihara K Ann Transl Med. 2023; 11(8):295.

PMID: 37181337 PMC: 10170281. DOI: 10.21037/atm-23-352.


Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.

Kinney A, Walters S, Lin Y, Lu S, Kim A, Ani J J Clin Oncol. 2023; 41(15):2767-2778.

PMID: 36787512 PMC: 10414736. DOI: 10.1200/JCO.22.00751.


Personalized Disease Prevention (PDP): study protocol for a cluster-randomized clinical trial.

Taksler G, Le P, Hu B, Alberts J, Flynn A, Rothberg M Trials. 2022; 23(1):892.

PMID: 36273151 PMC: 9587586. DOI: 10.1186/s13063-022-06750-7.


Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.

Kukafka R, Pan S, Silverman T, Zhang T, Chung W, Terry M JAMA Netw Open. 2022; 5(7):e2222092.

PMID: 35849397 PMC: 9294997. DOI: 10.1001/jamanetworkopen.2022.22092.


Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.

Linfield D, Rothberg M, Pfoh E, Noss R, Cassard L, Powers J Breast Cancer Res Treat. 2022; 195(2):153-160.

PMID: 35842521 DOI: 10.1007/s10549-022-06523-5.